Accession Number : ADA323710
Title : Analysis of Investigational Drugs in Biological Fluids. Method Development and Routine Assay. Appendix A.
Descriptive Note : Final rept. 15 Jan 92-14 Jan 97,
Corporate Author : CALIFORNIA UNIV SAN FRANCISCO
Personal Author(s) : Lin, Emil T.
PDF Url : ADA323710
Report Date : 13 FEB 1997
Pagination or Media Count : 274
Abstract : Using the procedures described in this report, we were able to work sequentially or simultaneously on eleven projects: (1) WR 238,605, (2) halofantrine (and its metabolite), (3) WR 6026 (and its metabolites), (4) mefloquine (and its metabolite), (5) artelinic acid, (6) p-aminoheptanophenone (and related compounds), (7) primaquine (and its metabolite), (8) gentamicin and paromomycin, (9) pyridostigmine, (10) chloroquine (and its metabolites), and (11) a multiple drug interaction study in dog plasma for WR 238,605, mefloquine, chloroquine, quinine, doxycycline, and halofantrine with additional work on development and validation of LC/MS/MS methods for halofantrine (and its metabolite), WR 238,605) in terms of method development, validation, and characterization. We worked on demonstrating sensitivity, specificity, linearity, lack of interferences, accuracy, and reproducibility of the analytical method, describing the extent of recovery for the method, and reporting on the stability of compounds of interest in specimens during storage and drug analysis to provide documentation in support of Investigational New Drug (IND) submissions to the Food and Drug Administration (FDA).
Descriptors : *ANTIDOTES, *PHARMACOKINETICS, *RADIOPROTECTIVE AGENTS, *ANTIPARASITIC DRUGS, MILITARY REQUIREMENTS, COMBAT READINESS, TOXICITY, RESPONSE(BIOLOGY), METABOLITES, URINE, PYRIDINES, ANTIBIOTICS, BIOASSAY, BLOOD PLASMA, DISINFECTION, BIOLOGICAL LABORATORIES, CHLOROQUINE, BILE, PERMISSIBLE DOSAGE, PRIMAQUINE, QUININE.
Subject Categories : Toxicology
Military Operations, Strategy and Tactics
Distribution Statement : APPROVED FOR PUBLIC RELEASE